Zolak/iStock via Getty Images
Shares of Trevi Therapeutics (NASDAQ:TRVI) tumbled 23% Tuesday post-market after the company reported topline results from a human abuse potential study of its drug Haduvio, or oral nalbuphine, for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and refractory